Table 1.
Effect of VA and DEX on SBP and HR in DOX-induced cardiotoxicity at day 1 and 28. Values are mean ± SEM, n = 6.
| Groups (mg/kg) | SBP 1 (mmHg) | SBP 28 (mmHg) | P value | HR 1 (bpm) | HR 28 (bpm) | P value |
|---|---|---|---|---|---|---|
| Normal saline | 121.9 ± 2.3 | 122.5 ± 4.5 | 0.54 | 342 ± 14.3 | 339 ± 16.1 | 0.16 |
| DOX | 121.3 ± 2.7 | 88 ± 4.1### | 0.000 | 360 ± 20.1 | 276 ± 15.5### | 0.000 |
| DEX + DOX | 118.9 ± 4.5 | 87± 2.3 | 1.2 | 365 ± 17.2 | 280 ± 14.8 | 2.2 |
| VA 10 + DOX | 124 ± 3.2 | 99 ± 3.7* | 0.03 | 350 ± 16 | 278 ±17.3 | 1.2 |
| VA 20 + DOX | 117.5 ± 3.7 | 109 ± 4.9*** | 0.000 | 355 ± 20.1 | 319.4 ± 17*** | 0.000 |
| VA 40 + DOX | 122.3 ± 4.1 | 114 ± 3.1*** | 0.000 | 350 ±15.3 | 334 ±13.3*** | 0.000 |
VA, Vanillic acid; DEX, dexrazoxane; DOX, doxorubicin; SBP, systolic blood pressure, HR, heart rate; ###P < 0.001 indicates significant differences versus normal saline control; and *P < 0.05 and ***P < 0.001 versus DOX group.